You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
NORTHBROOK, Ill., Jan. 21, 2016 – Astellas has been named one of Corporate Knights' 2016 Global 100 Most Sustainable Corporations in the World. Corporate Knights revealed this year’s honorees today at the World Economic Forum in Davos, Switzerland.
Corporate Knights analyzes data from all publicly traded companies with a market capitalization of at least US $2 billion. The organization analyzed data from 4,600 companies against their global industry peers on a list of 12 environmental and financial indicators.
“Because the indicators are quantitative and clearly defined, the results of the Global 100 are objective and replicable, and more akin to a financial index than many other ‘sustainability’ indices,” said Corporate Knights CEO Toby A.A. Heaps. “Astellas is a great example of a company that is taking a best-in-class approach to corporate sustainability.”
In recent years, Astellas has received several honors for its sustainable business practices, including the Newsweek Green Rankings, the FTSE4Good Index and the Dow Jones Sustainability Index.
“This recognition is another testament to the commitment of Astellas employees worldwide to our corporate, social and environmental responsibilities,” said Jeff Winton, senior vice president , Corporate Affairs and chief communications officer at Astellas Americas. “We are passionate about turning innovative science into value for patients, always with an eye toward sustaining resources for future generations.”
Sustainability highlights at the Astellas headquarters for the Americas in Northbrook, Illinois, include:
For information on the Global 100 index's full rankings, please visit: www.corporateknights.com/reports/global-100.
About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS. Visit our Facebook page at www.facebook.com/AstellasUS.
Get only the email alerts you want.
For media inquiries and reporter requests, please email us at corporate.communications@us.astellas.com.
Our communications team will respond to verified media requests within 24-48 hours as appropriate.
If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.